Biotechnology

United Therap

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

James Edgemond Sells United Therapeutics Stock

Joint Treatment CFO Exercises Stock Options and Sells Shares

United Therapeutics to Present New Data on Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension at ATS

RBC Downgrades United Therapeutics Target Price But Maintains Outperform Rating

CEO of United Therapeutics Sells Shares

FactSet Lowers EPS Estimates for United Therapeutics for 2026

United Therapeutics Announces Q1 2026 Earnings, Tyvaso and Ralinepag Clinical Trials Progress Well

United Therapeutics released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 781.5 M (forecast USD 797.38 M), actual EPS USD 5.82 (forecast USD 6.8576)

United Therapeutics reports Q1 net income of $274.9 million

Unity Therapeutics CEO Martin Ros 布拉特在此处似乎出现拼写错误，正确的应该是 Martin Ros 布拉特 (姓名未知，可能为 Martin Ros 布拉特错误) ブラ特 Exercised Stock Options and Sold 9,500 Shares at $146.03 per Share

United Therapeutics to Release FY2026 Q1 Earnings on May 6 Pre-Market EST, Forecast Revenue USD 797.38 M, EPS USD 6.8576

Chief Financial Officer of Uniting Therapeutics Exercises Stock Options and Sells Shares

Martin Ros 布拉特 Sells Joint Therapy Company Stocks

CEO of United Therapeutics Exercised Stock Options to Sell $5.42 Million Worth of Shares

Amesite

Meiwu Tech

InMed Pharmaceuticals

Generation Income Properties

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Gen Digital - Rights

NextNRG

UTHR

PLTR

PTIR

AAPB

AAPU

PLTG

Renaissance Technologies reported a -4.58% return in Q1 2026, slightly better than the S&P 500's -4.63%. Its Q1 holdings, valued at $63.9 billion, show a focus on technology, healthcare, and financial services. Top holdings include United Therapeutics (UTHR) with a quant rating of 3.00 (Hold), Palantir Technologies (PLTR) at 3.43 (Hold), and Apple (AAPL) at 3.49 (Hold). Other notable ratings include Micron Technology (MU) at 4.99 (Strong Buy) and Chevron (CVX) at 4.94 (Strong Buy).

- Renaissance Technologies reported a return of -4.58% in Q1 2026, slightly better than the S&P 500 index's decline of 4.63%.  
- The firm disclosed its Q1 2026 holdings through a 13F filing, revealing a long equity portfolio valued at approximately $63.9 billion.  
- This performance indicates a marginal advantage over the broader market during the same period.

Micron Tech

Chevron

Palantir Tech

GraniteShares 2x Long PLTR Daily ETF

GraniteShares 2x Long AAPL Daily ETF

Direxion Daily AAPL Bull 2X Shares

Leverage Shares 2X Long PLTR Daily ETF

Apple

S&P 500

Quant ratings on Renaissance Technologies' top holdings: UTHR, PLTR, AAPL

United Therapeutics' phase 3 trial of ralinepag for pulmonary arterial hypertension met its primary endpoint, reducing clinical worsening events by 55% compared to placebo. The company plans to file a new drug application with the FDA in H2 2026.

Fidelity

United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial

BIDU

U.S. stock futures are lower as investors watch Baidu Inc. (BIDU) expected to report earnings of $1.69 per share on $4.66 billion revenue, with shares down 5.6% to $135.33. Brady Corp. (BRC) anticipates earnings of $1.35 per share on $406.07 million revenue, shares fell 0.3% to $70.96. United Therapeutics (UTHR) received FDA clearance for a clinical trial, shares up 0.3% to $570.10. XP Inc. (XP) expected to report earnings of 48 cents per share, shares down 0.7% to $17.47. Ryanair (RYAOF) projected to post a loss of 95 cents per share, shares down 0.1% to $53.34.

- U.S. stock futures are trading lower, affecting several companies' earnings reports today.  
- Baidu Inc. is expected to report earnings of $1.69 per share, while Brady Corp. is projected at $1.35 per share, with both releasing earnings before the market opens.  
- United Therapeutics received FDA clearance for a clinical trial, impacting its shares positively, while XP Inc. and Ryanair are also scheduled to announce their quarterly earnings later today.

fidelity

Baidu

BIDU-SW

Brady

Ryanair

BIDU-SWR

Ryanair Holdings Plc

Baidu, Brady And 3 Stocks To Watch Heading Into Monday

TD Cowen analyst Joseph Thome has reaffirmed a Buy rating on United Therapeutics (UTHR) with a price target of $675.00. Thome, who focuses on the Healthcare sector, has an average return of 21.7% and a 55.38% success rate. Additionally, Wells Fargo also issued a Buy rating for UTHR, while Oppenheimer assigned a Hold rating on May 11.

Tip Ranks

Viridian Therapeutics

Xenon Pharma

Wells Fargo

Oppenheimer

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 | UTHR Stock News

StockTitan

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 | UTHR Stock News

PLTU

In a volatile market, investors are turning to low-risk stocks. This article highlights three companies: Citizens Financial Group, a US bank focusing on AI and efficiency; United Therapeutics, a biotech firm developing therapies for pulmonary conditions; and Palantir Technologies, which provides data software for defense and commercial sectors. Each company shows strong revenue potential but faces unique risks, including market competition and regulatory scrutiny. Investors should weigh these factors against growth forecasts and valuations.

- Government bond yields are rising, impacting market conditions, leading investors to seek resilient stocks, highlighted by the Low-Risk Leaders screener.  
- The article discusses three companies: Citizens Financial Group, United Therapeutics, and Palantir Technologies, each noted for their strong financial health and growth potential despite underlying risks.  
- The Low-Risk Leaders screen reveals additional potential investment opportunities, emphasizing the importance of thorough investment analysis and monitoring market dynamics.

Simplywall

Citizens Financial

Direxion Daily PLTR Bull 2X Shares

SAP AG-Sponsored

Accenture

Stellantis NV

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

SAP SE

3 Low Risk Leaders Powering AI, Pulmonary Drugs And Defense

CFO James Edgemond of United Therapeutics (NASDAQ:UTHR) sold 10,000 shares at an average price of $574.47, totaling $5,744,700. This sale decreased his ownership by 34.63%, leaving him with 18,876 shares valued at approximately $10.84 million. Edgemond has made several similar transactions recently, contributing to a cautious sentiment among investors due to significant insider selling.

Market Beat

Liquidia Tech

United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

James Edgemond, CFO of United Therapeutics, sold 10,000 shares for $5,744,746 on May 14, 2026. Following the SEC Form 4 filing, he retains control over 18,876 common shares.

United Therapeutics Insider Sold Shares Worth $5,744,746, According to a Recent SEC Filing

United Therap(UTHR.US)

Quant ratings on Renaissance Technologies' top holdings: UTHR, PLTR, AAPL

United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial

Baidu, Brady And 3 Stocks To Watch Heading Into Monday

TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 | UTHR Stock News

3 Low Risk Leaders Powering AI, Pulmonary Drugs And Defense

United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Insider Sold Shares Worth $5,744,746, According to a Recent SEC Filing